Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.

BMC cancer - 10 May 2021

Jarry Ulrich, Bostoën Mégane, Pineau Raphaël, Chaillot Laura, Mennessier Valentine, Montagne Pierre, Motte Emilie, Gournay Marjorie, Le Goff Arnaud, Guillaudeux Thierry, Pedeux Rémy

Abstract excerpt

BACKGROUND: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) in lung cancer. However, although this molecule is not subject to some of the resistance mechanisms observed in response to first generation TKIs, ultimately, patients relapse because of unknown resistance mechanisms. New relevant non-small cell lung cancer (NSCLC) mice models are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mice, Inbred BALB C

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33971844
DOI: 10.1186/s12885-021-08205-9
PMCID: PMC8111918

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.PMID 33971844Read ↗

Development and Characterization of Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain MetastasesSemantic proximity Read ↗

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.Semantic proximity Read ↗

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.Semantic proximity Read ↗

Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.Semantic proximity Read ↗

Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice.Semantic proximity Read ↗

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.Semantic proximity Read ↗

Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.Semantic proximity Read ↗

Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice.Semantic proximity Read ↗

Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.Semantic proximity Read ↗

Successful xenotransplantation of human lung cancer correlates with the metastatic phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.